CN Patent

CN110520110A — 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2019-11-29 · 6y expired

What this patent protects

本发明涉及包含5‑氯‑N4‑[2‑(二甲基磷酰基)苯基]‑N2‑{2‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]苯基}嘧啶‑2,4‑二胺作为活性药物成分的药物组合物，以及所述药物制剂的治疗用途。具体而言，本发明涉及包含所述药物组合物的片剂、制备所述片剂的方法以及所述片剂的治疗用途。

USPTO Abstract

本发明涉及包含5‑氯‑N4‑[2‑(二甲基磷酰基)苯基]‑N2‑{2‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]苯基}嘧啶‑2,4‑二胺作为活性药物成分的药物组合物，以及所述药物制剂的治疗用途。具体而言，本发明涉及包含所述药物组合物的片剂、制备所述片剂的方法以及所述片剂的治疗用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110520110A
Jurisdiction
CN
Classification
—
Expires
2019-11-29
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.